Psychedelics in Canada Conference

The Canadian Network for Biomarker Integration in Depression (CAN-BIND), in conjunction with the Ontario Brain Institute (OBI), will host a public dialogue on the use of psychedelics for psychiatric treatment and their emerging place in the Canadian Healthcare sector.

Our goal is to address various positions on this topic by presenting perspectives from academics, clinicians, those in the business and legal sectors, and people with lived experience.

We will focus on a discussion of the latest scientific evidence and the role of psychedelics in a therapeutic setting. We will then encourage a discussion among the public, medical professionals, and other vested interest groups about the future of psychedelics, their procurement, and utilization in Canada.